TY - JOUR
T1 - Receptor status of breast cancer diagnosed during pregnancy: A literature review
AU - Bakhuis, Carsten F. J.
AU - Suelmann, Britt B. M.
AU - van Dooijeweert, Carmen
AU - Linn, Sabine
AU - van der Wall, Elsken
AU - van Diest, Paul J.
N1 - Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.
AB - The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.
KW - Breast cancer
KW - Estrogen receptor
KW - HER2
KW - Pregnancy
KW - Progesterone receptor
U2 - 10.1016/j.critrevonc.2021.103494
DO - 10.1016/j.critrevonc.2021.103494
M3 - Review article
SN - 1040-8428
VL - 168
JO - Critical Reviews in Oncology Hematology
JF - Critical Reviews in Oncology Hematology
M1 - 103494
ER -